Disease · MONDO_0005231
Trials933
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 18 more are not shown, since the checks do not confirm them.
1 to 20 of 933
Download this page as JSON| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01070550 | PROPHESYS 1: An Observational Study on Predictors of Response in Treatment-naïve Patients With Chronic Hepatitis C Virus (HCV)Treated With Pegasys (Peginterferon Alfa-2a) | 4,680 | 2016-06-15 | Hepatitis C, Chronic | PEGINTERFERON ALFA-2A, RIBAVIRIN | Its record names the disease | ClinicalTrials.gov | |
| NCT00081770 | Peginterferon Dose Evaluations for Previously Untreated Subjects With Chronic Hepatitis C Infected With Genotype 1 (Study P03471) | Phase 3 | 4,469 | 2009-10-30 | Hepatitis C, Chronic | PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN | Its record names the disease | ClinicalTrials.gov |
| NCT01667081 | Durability of Virologic Response and/or Viral Resistance Patterns in Participants With Chronic Hepatitis C Who Have Been Previously Treated With Grazoprevir (MK-5172) (MK-5172-017) | 2,438 | 2022-06-06 | Hepatitis C | GRAZOPREVIR | Its record names the disease | ClinicalTrials.gov | |
| NCT00724893 | Efficacy of Pegetron® Redipen™ Treatment and Treatment Compliance of Patients With Chronic Hepatitis C in Canada (P04423) | 2,430 | 2013-11-20 | Hepatitis C, Chronic, Hepatitis C | PEGINTERFERON ALFA-2B, RIBAVIRIN | Its record names the disease | ClinicalTrials.gov | |
| NCT01066793 | PROPHESYS 2: An Observational Study on Predictors of Response in Treatment-naïve Patients With Chronic Hepatitis C Treated With Pegasys (Peginterferon Alfa-2a) or Peginterferon-alfa-2b | 2,343 | 2016-05-09 | Hepatitis C, Chronic | PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B | Its record names the disease | ClinicalTrials.gov | |
| NCT00039871 | PEG-Intron Plus Rebetol Treatment of Chronic Hepatitis C Subjects Who Failed Response to Alpha-Interferon Plus Ribavirin (Study P02370) | Phase 3 | 2,333 | 2008-12-11 | Hepatitis, Hepatitis C, Chronic, Fibrosis, Liver Cirrhosis | PEGINTERFERON ALFA-2B, RIBAVIRIN | Its record names the disease | ClinicalTrials.gov |
| NCT00727311 | Real-life Surveillance Study of Patients With Chronic Hepatitis C Treated With PegIntron Injector and Rebetol (Study P04538)(COMPLETED) | 2,302 | 2011-01-10 | Hepatitis C, Chronic, Hepatitis C | PEGINTERFERON ALFA-2B, RIBAVIRIN | Its record names the disease | ClinicalTrials.gov | |
| NCT00727259 | Evaluation of Satisfaction in Patients Receiving PegIntron Pen/Rebetol for Hepatitis C (Study P04067) | 1,995 | 2009-08-06 | Hepatitis C, Chronic | PEGINTERFERON ALFA-2B, RIBAVIRIN | Its record names the disease | ClinicalTrials.gov | |
| NCT01066819 | PROPHESYS 3: Observational Study on Predictors of Response in Patients With Treatment-naïve Chronic Hepatitis C Initiated on Treatment With Pegasys (Peginterferon Alfa-2a) or Peginterferon-alfa-2b | 1,656 | 2016-08-08 | Hepatitis C, Chronic | PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN | Its record names the disease | ClinicalTrials.gov | |
| NCT02219490 | A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection | Phase 3 | 1,596 | 2023-04-07 | Chronic Hepatitis C Virus (HCV) Infection Genotype 1 | DASABUVIR, OMBITASVIR, PARITAPREVIR, RIBAVIRIN, RITONAVIR | Its record names the disease | ClinicalTrials.gov |
| NCT00705432 | Safety and Efficacy of Boceprevir in Previously Untreated Subjects With Chronic Hepatitis C Genotype 1 (Study P05216AM2) (COMPLETED) | Phase 3 | 1,472 | 2011-06-14 | Hepatitis C, Chronic | BOCEPREVIR, PEGINTERFERON ALFA-2B, RIBAVIRIN | Its record names the disease | ClinicalTrials.gov |
| NCT00265395 | Extended Treatment With PEG-Intron® and Rebetol® in Patients With Genotype 1 Chronic Hepatitis C and Slow Virologic Response (Study P03685) | Phase 3 | 1,428 | 2009-07-08 | Hepatitis C, Chronic | INTERFERON ALFA-2B, RIBAVIRIN | Its record names the disease | ClinicalTrials.gov |
| NCT00723931 | PegIntron Injection Surveillance Plan (Study P04123) | 1,267 | 2010-12-13 | Hepatitis C, Chronic | PEGINTERFERON ALFA-2B | Its record names the disease | ClinicalTrials.gov | |
| NCT03537274 | Efficacy of Polyethylene Glycol-Interferon Alfa-2B (PEG-Intron, SCH 54031) Compared to Interferon Alfa-2B in Participants With Chronic Hepatitis C (MK-4031-016) | Phase 2/3 | 1,224 | 2019-04-09 | Hepatitis C | INTERFERON ALFA-2B | Its record names the disease | ClinicalTrials.gov |
| NCT00724854 | Evaluation of Rapid Virologic Response Among HCV Patients Treated With PegIntron and Rebetol in Brazil (Study P05427) | 1,146 | 2011-01-10 | Hepatitis C, Chronic, Hepatitis C | PEGINTERFERON ALFA-2B, RIBAVIRIN | Its record names the disease | ClinicalTrials.gov | |
| NCT00724451 | Observational Study Assessing Chronic Hepatitis C Management in Clinical Practice in Italy (Study P05488 AM1) | 1,128 | 2012-10-31 | Hepatitis C, Hepatitis C, Chronic | PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN | Its record names the disease | ClinicalTrials.gov | |
| NCT00627926 | A Phase 3 Study of Telaprevir in Combination With Pegasys® and Copegus® in Treatment-Naive Subjects With Genotype 1 Hepatitis C Virus (HCV) | Phase 3 | 1,095 | 2011-07-21 | Hepatitis C | PEGINTERFERON ALFA-2A, RIBAVIRIN, TELAPREVIR | Its record names the disease | ClinicalTrials.gov |
| NCT01318694 | Efficacy and Safety of Alisporivir Triple Therapy in Chronic Hepatitis C Genotype 1 Treatment-naïve Participants | Phase 3 | 1,081 | 2016-09-30 | Hepatitis C | ALISPORIVIR, PEGINTERFERON ALFA-2A, RIBAVIRIN | Its record names the disease | ClinicalTrials.gov |
| NCT00006164 | Long Term Interferon for Patients Who Did Not Clear Hepatitis C Virus With Standard Treatment | Phase 3 | 1,050 | 2009-09-04 | Chronic Hepatitis c, Cirrhosis, Liver, Fibrosis, Liver, Hepatic Cirrhosis | PEGINTERFERON ALFA-2A, RIBAVIRIN | Its record names the disease | ClinicalTrials.gov |
| NCT02607800 | Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir and Sofosbuvir/Velpatasvir in Adults With Chronic HCV Infection Who Have Not Previously Received Treatment With Direct-Acting Antiviral Therapy | Phase 3 | 943 | 2017-11-08 | Hepatitis C | SOFOSBUVIR, VELPATASVIR, VOXILAPREVIR | Its record names the disease | ClinicalTrials.gov |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005231/trials